NCT04818671 2026-01-22
ADAPTSC+
argenx
Phase 3 Completed
Clinical Trials
28 trialsNCT06764160 2026-01-15
ECU-MG-304
Alexion Pharmaceuticals, Inc.
Phase 3 Completed
NCT05681715 2025-11-06
A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)
UCB Pharma
Phase 3 Completed
NCT04980495 2025-11-05
ADAPT NXT
argenx
Phase 3 Completed
NCT06471361 2025-09-26
A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis
UCB Pharma
Phase 3 Completed
NCT05514873 2025-09-03
An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors
UCB Pharma
Phase 3 Completed
NCT04115293 2025-07-16
RAISE
UCB Pharma
Phase 3 Completed
NCT05737160 2025-05-23
Study of Telitacicept in Generalized Myasthenia Gravis
RemeGen Co., Ltd.
Phase 3 Completed
NCT04650854 2025-04-18
A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis
UCB Pharma
Phase 3 Completed
NCT03759366 2024-12-11
A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)
Alexion Pharmaceuticals, Inc.
Phase 3 Completed
NCT02950155 2024-10-26
Rinomax
Karolinska Institutet
Phase 3 Completed
NCT03920293 2024-05-28
Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 3 Completed
NCT03304054 2024-03-12
Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG
Catalyst Pharmaceuticals, Inc.
Phase 3 Completed
NCT04124965 2023-09-05
A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
UCB Pharma
Phase 3 Completed
NCT03770403 2023-07-14
ADAPT+
argenx
Phase 3 Completed
NCT05039190 2023-03-08
MG
Harbour BioMed (Guangzhou) Co. Ltd.
Phase 3 Completed
NCT04735432 2023-02-28
ADAPTsc
argenx
Phase 3 Completed
NCT02774239 2023-02-21
SCIG-MG
University of Alberta
Phase 3 Completed
NCT01727193 2022-04-14
The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy
First Affiliated Hospital, Sun Yat-Sen University
Phase 3 Completed
NCT03669588 2022-02-08
ADAPT
argenx
Phase 3 Completed
NCT02301624 2020-02-05
Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 3 Completed
NCT01997229 2019-07-16
Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)
Alexion Pharmaceuticals, Inc.
Phase 3 Completed
NCT00294658 2017-05-23
Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy
University of Alabama at Birmingham
Phase 3 Completed
NCT01325571 2016-03-09
A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia Gravis
Astellas Pharma Inc
Phase 3 Completed
NCT00285350 2015-03-25
Mycophenolate Mofetil in Myasthenia Gravis
FDA Office of Orphan Products Development
Phase 3 Completed
NCT00309088 2014-08-25
FK506 Phase 3 Study: a Study for Steroid Non-resistant Myasthenia Gravis (MG) Patients
Astellas Pharma Inc
Phase 3 Completed
NCT00309101 2009-06-03
An Open Study for Steroid Resistant, Non-Thymectomized MG Patients
Astellas Pharma Inc
Phase 3 Completed
NCT00306033 2006-04-03
Intravenous Immune Globulin Treatment Compared to Placebo in Patients With Myasthenia Gravis
University Health Network, Toronto
Phase 3 Completed